



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: May 21, 2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. MAY 21, 2019

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 21, 2019 duly approved and took on record the Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2019.

M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the standalone and consolidated Financial Results of the Company for the year ended 31st March, 2019.

Please find enclosed herewith the duly signed Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2019 alongwith the Auditor's Report and Declaration for unmodified opinion.

The meeting of the Board of Directors commenced at 1:00 p.m. and concluded at 4:10 p.m.

This is for your information and record.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer

Encl.:a/a

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

**INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED**

1. We have audited the accompanying Statement of Standalone Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the year ended 31/03/2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended 31/03/2019.



5. The Statement includes the results for the Quarter ended 31/03/2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in black ink, appearing to read "Gaurav J Shah".

Gaurav J Shah
Partner
(Membership No. 35701)

AHMEDABAD, 21 May 2019



STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019

Particulars	[Rs. in Million except per share data]				
	For Quarter Ended			For Year Ended	
	March 31, 2019 (Audited) (refer note 4)	December 31, 2018 (Unaudited)	March 31, 2018 (Audited) (refer note 4)	March 31, 2019 (Audited)	March 31, 2018 (Audited)
Revenue from Operations					
Sale of products	1,946.12	2,267.61	1,899.68	8,811.28	7,323.36
Other operating income	38.18	40.42	41.06	154.11	282.65
Total Revenue from Operations	1,984.30	2,308.03	1,940.74	8,965.39	7,606.01
Other Income	116.00	101.54	82.02	324.99	282.23
Total Income	2,100.30	2,409.57	2,022.76	9,290.38	7,888.24
Expenses					
Cost of materials consumed	115.44	199.01	125.24	581.88	470.79
Purchase of stock-in-trade	294.78	246.15	167.25	875.61	648.90
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(106.75)	(107.75)	(6.24)	(133.99)	(35.43)
Employee benefits expense	410.38	416.62	356.91	1,667.66	1,308.45
Finance Costs	43.83	50.94	77.23	227.93	104.29
Depreciation and amortisation expense	100.35	83.93	77.69	315.89	217.92
Other expenses	651.25	647.99	575.93	2,637.64	2,054.43
Total Expenses	1,509.28	1,536.89	1,374.01	6,172.62	4,769.35
Profit before Tax	591.02	872.68	648.75	3,117.76	3,118.89
Tax Expense					
Current Tax	132.17	191.94	140.43	688.67	679.46
Deferred Tax	(65.31)	(108.03)	(66.64)	(424.72)	(497.12)
Total Tax Expense	66.86	83.91	73.79	263.95	182.34
Net Profit for the period	524.16	788.77	574.96	2,853.81	2,936.55
Other Comprehensive Income	(1.98)	0.33	2.95	(0.99)	(0.73)
Items that will not be reclassified to profit or loss	(3.05)	0.51	4.51	(1.52)	(1.12)
Income tax relating to items that will not be reclassified to profit or loss	1.07	(0.18)	(1.56)	0.53	0.39
Total Comprehensive Income	522.18	789.10	577.91	2,852.82	2,935.82
Paid Up Equity Share Capital (Face Value of Re.1 each)	137.52	137.52	137.50	137.52	137.50
Other Equity				11,422.55	8,544.29
Earnings Per Share (of Re. 1 each) (not annualised) :					
Basic	3.81	5.74	4.18	20.75	21.36
Diluted	3.81	5.74	4.18	20.74	21.36
See accompanying notes to the financial results					



Jaini Shah



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 / 71841000

• Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results
1. Statement of Standalone Audited Assets and Liabilities
(Rs. in Million)

Particulars	As at	As at
	March 31, 2019	March 31, 2018
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	538.33	504.85
(b) Capital work-in-progress	7.48	-
(c) Goodwill	166.60	166.60
(d) Other Intangible assets	4,133.54	4,226.02
(e) Intangible assets under development	19.82	-
(f) Financial assets		
Investments	2,743.63	4,518.37
Other financial assets	76.18	101.27
(g) Income tax assets (net)	67.13	68.24
(h) Deferred tax assets (net)	1,377.76	952.51
(i) Other non-current assets	75.51	-
Total Non current assets	9,205.98	10,537.86
(2) Current assets		
(a) Inventories	747.03	575.20
(b) Financial assets		
Investments	3,061.05	937.59
Trade receivables	758.98	604.96
Cash and cash equivalents	64.64	88.08
Other bank balances	0.07	0.06
Loans	20.38	403.71
Other financial assets	112.61	75.27
(c) Other current assets	733.04	477.02
Total Current assets	5,497.80	3,161.89
TOTAL- ASSETS	14,703.78	13,699.75
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Equity Share capital	137.52	137.50
(b) Other Equity	11,422.55	8,544.29
Total Equity	11,560.07	8,681.79
(2) Non-current Liabilities		
(a) Financial Liabilities		
Long term Borrowings	-	2,736.88
Other financial liabilities	18.32	17.74
(b) Long-term provisions	164.73	150.16
(c) Other non-current liabilities	54.21	11.06
Total Non-current liabilities	237.26	2,915.84
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables		
i) Due to Micro and Small Enterprises	9.61	-
ii) Due to other than Micro and Small Enterprises	739.67	790.30
Other financial liabilities	1,760.39	1,030.26
(b) Short-term provisions	192.22	160.11
(c) Other current liabilities	190.03	95.88
(d) Income tax liabilities (net)	14.53	25.57
Total Current liabilities	2,906.45	2,102.12
Total Liabilities	3,143.71	5,017.96
TOTAL- EQUITY AND LIABILITIES	14,703.78	13,699.75



Jatin Jain

2. The above statement of financial results ("the Statement") of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 21, 2019.
3. The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
4. The figures for the quarter ended March 31, 2019 and quarter ended March 31, 2018 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year.
5. The Company has acquired Indian domestic formulation business of Strides Shasun Limited on a going concern basis by way of slump sale on November 30, 2017. Accordingly, figures for the current periods are not comparable with previous periods.
6. Revenue from operation upto June 30, 2017 was reported inclusive of excise duty which is now subsumed in Goods and Services Tax (GST). Accordingly, figures of revenue from operations for the year ended March 31, 2019 are not comparable with the figures of the previous year.
7. Effective from April 01, 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.
8. The Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 millions. The Company has acquired remaining 17.81% shareholding subsequently on April 06, 2019 for a consideration of ₹ 213.73 millions in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
9. Figures for the previous periods have been regrouped/reclassified wherever considered necessary.



Amit Bakshi



For Eris Lifesciences Limited,

Place: Ahmedabad
Date: 21st May, 2019

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

**INDEPENDENT AUDITORS' REPORT
TO THE BOARD OF DIRECTORS OF
ERIS LIFESCIENCES LIMITED**

1. We have audited the accompanying Statement of Consolidated Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the year ended 31 March 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by other auditors in terms of their reports referred to in paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion.



4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and the other financial information of the subsidiaries referred to in paragraph 6 below, the Statement:
- a. includes the results of the following entities:
 - i. Eris Lifesciences Limited (Parent)
 - ii. Aprica Healthcare Private Limited (Subsidiary)
 - iii. Kinedex Healthcare Private Limited (Subsidiary)
 - iv. Eris Therapeutics Private Limited (Subsidiary)
 - v. UTH Healthcare Limited (Subsidiary)
 - vi. Eris Healthcare Private Limited (Subsidiary)
 - b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016; and
 - c. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, Total comprehensive income and other financial information of the Group for the year ended 31 March 2019.
5. We did not audit the financial statements / financial information of five subsidiaries included in the consolidated financial results, whose financial statements / financial information reflect total assets of Rs. 963.94 millions as at 31 March, 2019, total revenues of Rs. 879.48 millions, total net profit after tax of Rs. 82.98 millions and total comprehensive income of Rs. 82.84 millions for the year ended on that date, as considered in the consolidated financial results. These financial statements / financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

6. The Statement includes the results for the Quarter ended 31 March 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



A handwritten signature in blue ink, appearing to read "Gaurav J Shah".

Gaurav J Shah
Partner
(Membership No. 35701)

AHMEDABAD, 21 May 2019



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013

Eris
Eris Lifesciences Ltd.

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019

Particulars	For Quarter Ended			For Year Ended	
	March 31, 2019 (Audited) (refer note 8)	December 31, 2018 (Unaudited)	March 31, 2018 (Audited) (refer note 8)	March 31, 2019 (Audited)	March 31, 2018 (Audited)
	(Rs. in Million except per share data)				
Revenue from Operations					
Sale of products	2,110.85	2,484.78	2,080.50	9,672.02	8,271.04
Other operating income	37.36	39.17	41.42	149.59	285.00
Total Revenue from Operations	2,148.21	2,523.95	2,121.92	9,821.61	8,556.04
Other Income	117.29	102.88	73.05	316.94	264.08
Total Income	2,265.50	2,626.83	2,194.97	10,138.55	8,820.12
Expenses					
Cost of materials consumed	115.44	199.01	125.24	581.88	470.79
Purchase of stock-in-trade	339.26	321.46	217.76	1,089.32	898.36
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(105.95)	(126.55)	(13.41)	(134.22)	(28.53)
Employee benefits expense	472.31	474.52	415.82	1,906.59	1,573.22
Finance Costs	44.33	51.08	77.55	228.95	105.50
Depreciation and amortisation expense	112.07	95.92	90.64	363.54	256.42
Other expenses	705.64	720.27	659.23	2,928.91	2,422.07
Total Expenses	1,683.10	1,735.71	1,572.83	6,964.97	5,697.83
Profit before Tax	582.40	891.12	622.14	3,173.58	3,122.29
Tax Expense					
Current Tax	132.63	198.01	139.57	710.71	687.93
Deferred Tax	(89.07)	(108.87)	(78.21)	(448.60)	(515.42)
Total Tax Expense	43.56	89.14	61.36	262.11	172.51
Net Profit for the period	538.84	801.98	560.78	2,911.47	2,949.78
Attributable to :					
- Owners of the Company	540.87	801.38	557.87	2,907.96	2,941.05
- Non controlling interest	(2.03)	0.60	2.91	3.51	8.73
Other Comprehensive Income	(2.94)	0.60	4.28	(1.13)	0.66
Items that will be reclassified to profit or loss	(4.27)	0.85	6.35	(1.71)	0.78
Income tax relating to items that will be reclassified to profit or loss	1.33	(0.25)	(2.07)	0.58	(0.12)
Total Comprehensive Income	535.90	802.58	565.06	2,910.34	2,950.44
Attributable to :					
- Owners of the Company	537.93	801.98	562.15	2,906.83	2,941.71
- Non controlling interest	(2.03)	0.60	2.91	3.51	8.73
Paid Up Equity Share Capital (Face Value of Re.1 each)	137.52	137.52	137.50	137.52	137.50
Other Equity				11,367.66	8,475.57
Earnings Per Share (of Re. 1 each) (not annualised) :					
Basic	3.93	5.83	4.06	21.15	21.39
Diluted	3.93	5.83	4.06	21.13	21.39
See accompanying notes to the financial results					



Jashin Shah



Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179402 - 03 * Fax: +91 - 79 - 30179404 / 30451001 / 71841000

* Email: eris@erislifesciences.com * Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

1. Statement of Audited Consolidated Assets and Liabilities

(Rs. in Million)

Particulars	As at	As at
	March 31, 2019	March 31, 2018
I. ASSETS :		
(1) Non-current assets		
(a) Property, Plant and Equipment	553.23	526.12
(b) Capital work-in-progress	7.48	-
(c) Goodwill	935.87	934.74
(d) Other Intangible assets	6,116.26	6,250.06
(e) Intangible assets under development	19.82	-
(f) Financial assets		
Investments	409.12	2,716.10
Other financial asset	76.87	101.91
(g) Income tax assets (net)	76.73	79.18
(h) Deferred tax assets (net)	1,447.94	1,005.67
(i) Other non-current assets	75.51	-
Total Non-current assets	9,718.83	11,613.78
(2) Current assets		
(a) Inventories	826.53	654.48
(b) Financial assets		
Investments	3,149.42	937.59
Trade receivables	839.76	666.42
Cash and cash equivalents	75.00	106.08
Other bank balances	0.07	0.30
Loans	21.25	11.84
Other financial assets	129.47	83.04
(c) Income tax assets (net)	1.26	-
(d) Other current assets	775.03	527.32
Total Current assets	5,817.79	2,987.07
TOTAL- ASSETS	15,536.62	14,600.85
II. EQUITY AND LIABILITIES :		
(1) Equity		
(a) Share capital	137.52	137.50
(b) Other Equity	11,367.66	8,475.57
Equity attributable to the owners of the company	11,505.18	8,613.07
Non-controlling Interest	183.11	246.65
Total Equity	11,688.29	8,859.72
(2) Non-current liabilities		
(a) Financial Liabilities		
Long term Borrowings	2.93	2,741.95
Other financial liabilities	23.51	22.59
(b) Long-term provisions	193.86	187.13
(c) Other non-current liabilities	55.71	12.16
(d) Deferred tax liabilities (net)	516.95	522.70
Total Non-current liabilities	792.96	3,486.53
(3) Current liabilities		
(a) Financial Liabilities		
Trade payables		
A) Due to Micro and Small Enterprises	9.61	-
B) Due to other than Micro and Small Enterprises	831.64	907.74
Other financial liabilities	1,763.84	1,034.36
(b) Short-term provisions	210.29	170.71
(c) Other current liabilities	221.88	116.22
(d) Income tax liabilities (net)	18.11	25.57
Total current liabilities	3,055.37	2,254.60
Total Liabilities	3,848.33	5,741.13
TOTAL- EQUITY AND LIABILITIES	15,536.62	14,600.85



Jahir Jahan



2. The above statement of financial results ("the Statement") of the Group were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 21, 2019.
3. The Group is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
4. The Group has acquired Indian domestic formulation business of Strides Shasun Limited on a going concern basis by way of slump sale on November 30, 2017. Accordingly, figures for the current periods are not comparable with previous periods.
5. Revenue from operation upto June 30, 2017 was reported inclusive of excise duty which is now subsumed in Goods and Services Tax (GST). Accordingly, figures of revenue from operations for the year ended March 31, 2019 are not comparable with the figures of the previous year.

6. Information of Standalone Financial Result of the Company is as under: (Rs. in Million)

Particulars	Quarter Ended			Year Ended	
	March 31, 2019 (Audited)	December 31, 2018 (unaudited)	March 31, 2018 (Audited)	March 31, 2019 (Audited)	March 31, 2018 (Audited)
Revenue from Operations	1,984.30	2,308.03	1,940.74	8,965.39	7,606.01
Profit Before Tax	591.02	872.68	648.75	3,117.76	3,118.89
Net Profit for the period	524.16	788.77	574.96	2,853.81	2,936.55

7. Effective from April 01, 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
8. The figures for the quarter ended March 31, 2019 and the quarter ended March 31, 2018 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year.
9. The Parent Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 millions. The Company has acquired remaining 17.81% shareholding subsequently on April 06, 2019 for a consideration of ₹ 213.73 millions in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
10. Figures for the previous periods have been regrouped/reclassified, wherever considered necessary.



Jashin Jhal



For Eris Lifesciences Limited,

Place: Ahmedabad
Date: 21st May, 2019


Amit Bakshi
Chairman and Managing Director
DIN : 01250925



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

Date: May 21, 2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	--

Dear Sir/Madam,

SUBJECT: DECLARATION IN RESPECT OF UNMODIFIED OPINION ON AUDITED FINANCIAL STATEMENTS FOR YEAR ENDED 31ST MARCH 2019

Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby declare that the Audited Financial Results (standalone & consolidated) for the Financial Year ended 31st March 2019 have been approved by the Board of Directors of the Company at their meeting held today i.e. 21st May 2019.

Our statutory Auditors M/s. Deloitte Haskins & Sells LLP, Chartered Accountants have issued Audit Report with unmodified opinion on the said financial results.

This is for your information and record.

For Eris Lifesciences Limited



Sachin Shah
Chief Financial Officer

Corporate Office:

7th Floor, Commerce House - IV, Nr. Prahlad Nagar, 100 Ft. Road, Ahmedabad - 380 015, Gujarat, India
Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

Registered Office:

21, New York Tower - A, Nr. Muktidham Temple, Thaltej Cross Road, Thaltej, Ahmedabad - 380 054, Gujarat, India • CIN: U24232GJ2007PLCO49867